A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario

Abstract

Introduction

This retrospective study investigates the efficacy of cemiplimab, a monoclonal antibody targeting the PD-1 receptor, in treating squamous cell carcinoma (SCC) of the skin.

Methods

The study analyzes data from 50 patients with SCC, focusing on various clinical parameters, including patient demographics, tumor characteristics, treatment history, disease status at the beginning of therapy, and survival outcomes.

Results

Of the patients who received at least one cycle of cemiplimab, 42% showed a clinical response. Adverse reactions were generally low, with the safety profile deemed excellent. During a median follow-up of 9.6 months, 17 patients experienced progression or death. Among these, 15 patients had died at the time of the analysis. The median progression-free survival (PFS) for the entire cohort was approximately 20.8 months, while median overall survival (OS) was not reached. Univariate Cox regression analysis for PFS showed that tumors in the arms and legs were associated with higher progression risk, while age above 65 years was not statistically significant. Distant metastasis exhibited a trend towards improved PFS. In terms of OS, distant metastasis was a significant predictor of reduced survival, while age above 65 years was not statistically significant. In a multivariate model, only the absence of distant metastasis remained significant, with an adjusted odds ratio (OR) of 12.3 (95% confidence interval 1.3–112.1).

Conclusion

These findings provide valuable insights into the real-world effectiveness of cemiplimab in SCC management.

Key Summary Points

This retrospective study assessed the efficacy of cemiplimab, a PD-1 inhibitor, in treating squamous cell carcinoma (SCC) of the skin in a real-world setting.

Among 50 patients with SCC, 42% exhibited a clinical response to cemiplimab treatment, with a median progression-free survival (PFS) of approximately 20.8 months.

Multivariate analysis identified the absence of distant metastasis as a significant predictor of a clinical response to cemiplimab.

The study highlights the favorable safety profile of cemiplimab in this patient population and the relevance of cemiplimab in elderly patients often excluded from clinical trials.

Introduction

Squamous cell carcinoma (SCC) of the skin poses a significant clinical challenge, impacting patients’ well-being and survival [1]. SCC is the second most common skin cancer, with risk factors including sun exposure, advanced age, and immunosuppression [2]. While most cases can be cured with surgery and/or radiotherapy, a small percentage becomes incurable as a result of metastasis or advanced progression [3]. These patients are considered for systemic therapy. In the quest to improve therapeutic outcomes while minimizing adverse effects, the landscape of SCC management has witnessed notable advancements over the years. Among these advancements, immune checkpoint inhibitors, particularly cemiplimab, have emerged as a promising avenue for the treatment of advanced SCC [4].

Cemiplimab, a monoclonal antibody targeting the programmed death 1 (PD-1) receptor, has exhibited substantial potential in the management of advanced SCC [5]. However, the real-world effectiveness of this therapeutic agent, especially within distinct patient populations and varied clinical scenarios, remains a subject of paramount interest [6].

This retrospective article embarks on an exploration of the efficacy of cemiplimab in SCC treatment. Drawing upon a dataset encompassing 50 patients diagnosed with SCC of the skin, we examine a comprehensive set of clinical variables. These variables encompass patient demographics, tumor characteristics, treatment history, disease status at the beginning of therapy, and survival outcomes. Our objective is to offer valuable insights into the practical application of cemiplimab in SCC management, shedding light on its efficacy profile within diverse clinical contexts.

Methods

Patient Population

This retrospective study was conducted at four participating medical institutions. A retrospective chart review retrieved data regarding eligible individuals aged 18 years or older with a confirmed diagnosis of SCC of the skin. Eligible patients must have undergone at least one cycle of cemiplimab treatment as part of their therapeutic regimen. Demographic information was gathered from each patient in this retrospective study of cemiplimab efficacy in SCC. Age, previous systemic therapy, previous radiotherapy, and previous surgery were assessed at baseline. Furthermore, this retrospective study also included information about conditions that may interact with cemiplimab effectiveness or toxicity, such as lymphoproliferative disorders and immunosuppressive or autoimmune conditions. Additionally, the binary variable “age ≥ 65” was used to distinguish patients aged 65 years or older at the initiation of cemiplimab therapy, allowing for the differentiation of older patient populations. Tumor location documented the anatomical regions affected, including the head and neck, arms and legs, trunk, and genitalia, providing insight into the primary site of SCC lesions. Disease status at the beginning of therapy at the time of cemiplimab initiation was stratified into “locally advanced progression only,” “regional metastasis only,” or “distant metastasis” at the initiation of cemiplimab therapy, reflecting the extent and nature of SCC progression.

Clinical outcomes were evaluated through progression-free survival (PFS), defined as the time in months from cemiplimab treatment initiation until disease progression or death, and overall survival (OS), measuring the period in months from initial SCC diagnosis to death or last follow-up. Lastly, response rate was defined as the number of patients showing either a partial or complete response based on clinical criteria divided by the total number of evaluable patients. These variables collectively provide a comprehensive understanding of the patient population and the study’s evaluation of cemiplimab’s effectiveness in SCC treatment.

Statistical Analysis

The primary end point of the study was clinical response rate. Secondary end points included the number of delivered cycles of cemiplimab, PFS, and OS. Descriptive statistics was used to provide a comprehensive overview of the patient cohort and treatment outcomes. Measures such as median and interquartile range were calculated for continuous variables like age and the number of treatment cycles. Categorical variables such as gender, tumor location, prior systemic therapy, radiotherapy, surgery, and disease status at the beginning of therapy were summarized using percentages. To assess survival outcomes, the Kaplan–Meier method was employed. PFS and OS were analyzed using Kaplan–Meier survival curves. As a result of the retrospective nature of the study and the utilization of anonymized data, formal permission from an ethical committee was not required for this research according to the Italian Medicines Agency (AIFA) guidelines. However, it adhered to the Helsinki Declaration.

Results

Study Cohort Characteristics

The patient cohort consisted of 50 patients, with a median age of 83 years. Notably, nearly all patients (96%) were aged 65 years or older at the initiation of cemiplimab therapy. In terms of gender, the majority of patients were male (70%). In the studied population, comorbidities were observed as follows: 20% of individuals had diabetes, 6% had severe renal insufficiency, 2% had alcoholic cirrhosis, while autoimmune diseases, lymphoproliferative disorders, and immunosuppressive medications were not reported in any cases, indicating a low prevalence of these conditions within the cohort. Tumor locations varied, with some patients having tumors in the head and neck (70%) and others in the trunk (12%). A smaller proportion had tumors in the arms or legs (16%) or the genitalia (2%). Twenty patients had received previous systemic therapy (40%) for SCC before starting cemiplimab treatment. Radiotherapy and surgery were also part of the treatment landscape, with 58% of patients receiving radiotherapy and 54% undergoing surgical intervention during their therapeutic journey. Among the observed disease status at the beginning of therapy, 16% of patients presented with locally advanced progression only. The majority (64%) had regional metastasis only, while 20% of patients exhibited distant metastasis (Table 1).

Table 1.

Characteristics of the study population

Variable	Value
Age, years, median [IQR]	83 [80–89]
Age ≥ 65	96%
Gender (male)	70%
Relevant comorbidities
Diabetes	20%
Severe renal insufficiency	6%
Autoimmune diseases	0%
Lymphoproliferative disorders	0%
Alcoholic cirrhosis	2%
Immunosuppressive medications	0%
Tumor location
Head and neck	70%
Arm/leg	16%
Trunk	12%
Genitalia	2%
Previous systemic therapy	40%
Radiotherapy	58%
Surgery	54%
Disease status at the beginning of therapy
Locally advanced only	16%
Regional metastasis only	64%
Distant metastasis	20%

Data are presented as a percentage unless otherwise specified#

IQR interquartile range

Treatment Safety and Effectiveness and Exploratory Analysis

The median number of treatment cycles was 10 (interquartile range 4–21). Of the 50 patients who received at least one cycle of cemiplimab, 42% demonstrated a clinical partial or complete response to cemiplimab.

Several adverse reactions were reported. Nausea was observed in 1 out of 50 participants (2%), while asthenia was reported in 9 out of 50 individuals (18%). Xerostomia was reported in 1 out of 50 participants (2%), as was dizziness (2%), rectorrhagia/urothelial carcinoma (UC) (2%), itch (2%), pneumonia (2%), and neutropenia (2%). Additionally, biliary lithiasis (gallstones) was observed in 1 out of 50 individuals (2%) (Table 2). The overall safety profile of the study appeared to be excellent (Table 2).

Table 2.

Adverse events associated with cemiplimab

Adverse events N = 50	G1	G2	G3	G4
Nausea		1/50 (2%)
Asthenia	9/50 (18%)	1/50 (2%)
Xerostomia	1/50 (2%)
Dizziness	1/50 (2%)
Rectorrhagia/UC	1/50 (2%)
Dermatitis		1/50 (2%)
Itch	1/50 (2%)
Pneumonia	1/50 (2%)	2/50 (4%)
Neutropenia				1/50 (2%)
Biliary lithiasis	1/50 (2%)

UC urothelial carcinoma

During a median follow-up time of 9.6 months, 17 patients experienced events of progression and/or death. Among these, 15 patients had died at the time of the analysis. The mean OS was 25.8 months (95% confidence interval (CI) for the mean OS 20.6–31.1 months), while the median OS was not reached. The mean PFS was approximately 23.24 months (95% CI for the mean PFS 18.2–29.4 months), while the median PFS for the entire study cohort was approximately 20.8 months) (Figs. 1 and 2). Table 3 presents the results of univariate logistic regression analysis examining the odds of achieving a clinical response. Notably, patients with tumors located in the arms and legs had significantly lower odds of a clinical response (odds ratio (OR) 0.21, 95% CI 0.04–0.98, p = 0.042). Similarly, age above 65 was associated with reduced odds of a clinical response (OR 0.24, 95% CI 0.09–0.61, p = 0.004), while the absence of distant metastasis significantly increased the odds of a clinical response (OR 5.31, 95% CI 1.77–15.94, p = 0.003). Importantly, when these three factors were entered into a multivariate model, only the absence of distant metastasis remained statistically significant, with an adjusted OR of 12.38 (95% CI 1.36–112.10). Notably, our analysis revealed that patients with tumors located in the arms and legs exhibited a significantly higher risk of progression (hazard ratio (HR)  8.09, 95% CI 1.66–39.33, p = 0.0095). Conversely, age above 65 (arbitrary cutoff) or above the median value of 83 years did not exhibit a statistically significant association with PFS (HR 0.50, 95% CI 0.06–3.79, p = 0.50 and HR 0.47, 95% CI 0.16–1.37, p = 0.16, respectively).

Fig. 1.

Kaplan–Meier plot illustrating progression-free survival (PFS) among patients with squamous cell carcinoma (SCC) treated with cemiplimab

Fig. 2.

Kaplan–Meier plot depicting overall survival (OS) in patients with squamous cell carcinoma (SCC) who received cemiplimab therapy

Table 3.

Univariate logistic regression analysis for clinical response

Variable	OR for clinical response	95% CI	p value
Tumor located in the arms and legs	0.211	0.045–0.982	0.042
Age ≥ 65	0.244	0.097–0.614	0.004
No distant metastasis	5.318	1.776–15.943	0.003
Tumor located in head and neck	3.042	0.921–10.039	0.067
Locally advanced progression only	3.042	0.921–10.039	0.067
Female	0.577	0.208–1.595	0.292
No previous systemic therapy	1.419	0.422–4.773	0.578
Received radiotherapy	1.105	0.397–3.076	0.862
Regional metastasis only	2.265	0.855–6.002	0.100
No surgery performed	0.624	0.197–1.980	0.413
Tumor located in the trunk	0.285	0.047–1.736	0.167

OR odds ratio, CI confidence interval

Interestingly, the absence of distant metastasis showed a trend towards improved PFS (HR 0.17, 95% CI 0.02–1.29, p = 0.0870). Notably, the presence of distant metastasis emerged as a significant predictor of reduced OS (HR 4.7, 95% CI 1.6–13.7, p = 0.003). Conversely, age above 65 (arbitrary cutoff) and above the median value of 83 years did not exhibit a statistically significant association with OS (HR 0.95, 95% CI 0.36–2.48, p = 0.925 and HR 0.38, 95% CI 0.12–1.22, p = 0.105, respectively).

Discussion

Squamous cell carcinoma of the skin is a clinical challenge, affecting both the well-being and survival of patients. Our study explores the real-world effectiveness of cemiplimab, a monoclonal antibody targeting the PD-1 receptor, in the treatment of advanced SCC. Through a retrospective analysis of a dataset encompassing 50 patients with SCC, we aimed to shed light on the practical application and effectiveness of cemiplimab within diverse clinical contexts. Our patient cohort consisted of 50 individuals, primarily elderly with a median age of around 83 years, and predominantly male (66%). Importantly, almost all patients (96%) were aged 65 years or older at the initiation of cemiplimab therapy. This demographic distribution underscores the relevance of our study in the context of a patient population often underrepresented in clinical trials. Encouragingly, our findings demonstrated that 42% of the patients who received at least one cycle of cemiplimab exhibited a clinical partial or complete response, with a median PFS of approximately 20 months and a median OS that was not reached. A central aspect of our analysis involved conducting univariate analyses to better understand the interplay of multiple factors in predicting treatment outcomes. When considering the influence of tumor location, age, and distant metastasis on clinical response, we found that the absence of distant metastasis was a significant predictor of a clinical response even after adjusting for other significant variables. Patients without distant metastasis had significantly higher odds of responding to cemiplimab treatment. This multivariate analysis reaffirms the importance of distant metastasis as a critical predictor of cemiplimab response in advanced SCC. Importantly, our analysis revealed that age, whether analyzed using arbitrary or median cutoffs, was not associated with either PFS or OS. This observation suggests that cemiplimab demonstrates effectiveness and tolerability across a wide age range, including the elderly. The lack of an association with age implies that the primary determinant of progression and mortality is not age itself but rather the underlying disease.

Overall, our results align with the growing body of evidence supporting the effectiveness of cemiplimab in the treatment of advanced SCC [7, 8]. Furthermore, the toxicity profile of cemiplimab in our study was notably favorable, with a low incidence of adverse events, suggesting its tolerability and safety in this patient population. In a pivotal phase 2, single-arm trial [9] conducted across 25 outpatient clinics in Australia, Germany, and the USA, cemiplimab demonstrated significant antitumor activity and an acceptable safety profile in patients diagnosed with locally advanced SCC of the skin. A total of 78 eligible patients aged 18 years or older, with histologically confirmed locally advanced cutaneous squamous cell carcinoma (cSCC) and an Eastern Cooperative Oncology Group performance status of 0–1, received cemiplimab intravenously at a dose of 3 mg/kg every 2 weeks for a maximum of 96 weeks. Findings from this study revealed a notable objective response in 44% (34 of 78) of the enrolled patients. Within this responsive group, 13% achieved a complete response, while 31% exhibited a partial response. Notably, grade 3–4 treatment-emergent adverse events were documented in 44% of patients, with hypertension affecting 8% and pneumonia occurring in 5% of cases. Furthermore, serious treatment-emergent adverse events were noted in 29% of patients. Importantly, one treatment-related death was reported, which was attributed to aspiration pneumonia. Importantly, the final analysis of the study [7] confirmed consistent and durable responses. The results displayed a remarkable OS rate at 48 months, with 61.8% (95% CI 54.0–68.7), underscoring the long-term effectiveness of cemiplimab in treating advanced cSCC. The median duration of response (DOR) was also substantial, with an overall median of 41.3 months.

Conversely, in a retrospective observational study [10], Baggi and colleagues examined the real-world data of cemiplimab in the treatment of locally advanced and metastatic SCC of the skin. The study encompassed patient records from 17 referral Italian centers, covering the period between May 2019 and February 2020. A total of 131 patients, with a median age of 79 years, were included in the analysis. Among them, 9.2% had concurrent chronic lymphoproliferative diseases, and 8.5% had concomitant autoimmune diseases. The safety profile was assessed on the basis of Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v 5.0), with 42.7% of patients experiencing at least one treatment-related adverse event (AE). Notably, 9.2% of patients encountered grade 3–4 adverse events, and two fatal adverse events were reported. The study revealed an overall response rate (ORR) of 58% and a disease control rate (DCR) of 71.7% among the patients. In another recent study, Denaro et al. [8] investigated the use of cemiplimab in ultra-octogenarian patients with cSCC at a tertiary referral center. The study included 20 patients, with a median age of 86.9 years, and assessed the efficacy and safety of cemiplimab treatment. Despite advanced age and comorbidities, the results indicated that cemiplimab was effective in this patient population, with a 65% response rate, including partial responses and long-lasting stable disease. The median duration of response was 14 months, and no treatment-related adverse events of grade 3 or higher were reported [8].

Importantly, in a phase 2 study exploring the neoadjuvant use of cemiplimab in resectable stage II–IV SCC of the skin [11], Gross and colleagues observed a substantial pathological complete response rate of 51%, indicating the potential effectiveness of cemiplimab in this context. In another study, multivariate analysis revealed a notable correlation between elevated serum interleukin (IL)-6 levels and shorter PFS, establishing IL-6 as an independent predictive factor for cemiplimab response [12]. Another clinical trial examining first-line pembrolizumab monotherapy for unresectable SCC of the skin suggested that PD-L1 positivity might serve as a predictive factor for a positive response to anti-PD-1 agents, such as cemiplimab. Specifically, the trial demonstrated that patients who were PD-L1-positive exhibited a significantly higher response rate (55%) compared to their PD-L1-negative counterparts (17%) [13].

It is crucial to recognize and address the limitations of our study. First, the retrospective nature of our research introduces inherent biases and prevents the establishment of causal relationships. Notably, the retrospective design may have led to an underestimation of toxicity. Furthermore, it is important to emphasize that this retrospective study lacked the availability of biomarkers for investigation. However, despite these limitations, the study’s strengths, including the sample size for a rare condition and the reflection of a real-world scenario, provide valuable insights into the practical application of cemiplimab.

Conclusion

Our study adds to the growing body of evidence supporting the potential benefit of cemiplimab in the treatment of advanced SCC. Multivariate analysis has shed light on the importance of factors such as distant metastasis, tumor location, and patient age in predicting treatment outcomes. While limitations exist, our findings underscore the relevance of cemiplimab, especially within the context of elderly and frail patients who are often excluded from clinical trials. Further research, including larger prospective trials with toxicity data and a broader patient population, is warranted to validate our observations and provide comprehensive guidance on treatment decisions for patients with advanced SCC in real-world settings.

Author Contributions

Aieta Michele, Leo Silvana, Domenico Bilancia, Rossella Di Trolio, Michela Rosaria, Iuliucci, Concetta Ingenito, Roberta Rubino, Arianna Piscosquito, Michele Caraglia, Marianna Donnarumma, Ferdinando Costabile, Raffaele Conca, Marco Pisino, Angelo Vaia, Luca Scafuri and Antonio Verde contributed to data collection and revision. Carlo Buonerba and Giuseppe Di Lorenzo were involved in the concept and design. Carlo Buonerba and Michela Rosaria Iuliucci were responsible for statistical analysis and drafting the paper.

Funding

No funding was received for this study or its publication.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of Interest

Giuseppe Di Lorenzo, Aieta Michele, Leo Silvana, Domenico Bilancia, Rossella Di Trolio, Michela Rosaria Iuliucci, Concetta Ingenito, Roberta Rubino, Arianna Piscosquito, Michele Caraglia, Marianna Donnarumma, Ferdinando Costabile, Raffaele Conca, Marco Pisino, Angelo Vaia, Luca Scafuri, Antonio Verde and Carlo Buonerba have nothing to disclose.

Ethical Approval

As a result of the retrospective nature of the study and the utilization of anonymized data, formal permission from an ethical committee was not required for this research according to the Italian Medicines Agency (AIFA) guidelines. However, it adhered to the Helsinki Declaration.